Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 29Leukemia 8Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 5Leukemia, Erythroblastic, Acute 5Congenital Abnormalities 5Myeloproliferative Disorders 4Leukemia, Megakaryoblastic, Acute 4Recurrence 3Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia, Basophilic, Acute 2Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

Cytarabine 11Cyclophosphamide 10Filgrastim 9Etoposide 8fludarabine phosphate 6Vorinostat 6Tacrolimus 6Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Dasatinib 6Carboplatin 5tipifarnib 4sargramostim 4Topotecan 4Sirolimus 4Bortezomib 4tanespimycin 3fludarabine 3alvocidib 3Whole-Body Irradiation 3Sorafenib 3Flow Cytometry 3Doxorubicin 3Decitabine 3Busulfan 3Antilymphocyte Serum 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3laromustine 2entinostat 2bryostatin 1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blast Crisis × Idarubicin × Clear all
NCT00331513 2013-09-30

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡